Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.32 |
| ▸ | HTR1D | P28221 | 5/20 | 0.32 |
| ▸ | HTR1B | P28222 | 5/20 | 0.32 |
| ▸ | HTR1A | P08908 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | HTR1F | P30939 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5170319 | 1.00 | KCNH2 (0.33) | KCNH2CACNA1CSCN5AIRAK4HTR1D | |
| SCHEMBL2155869 | 1.00 | KCNH2 (0.33) | KCNH2CACNA1CSCN5AIRAK4HTR1D | |
| SCHEMBL15905687 | 0.90 | HTR1D (0.32) | KCNH2CACNA1CSCN5AIRAK4HTR1D | |
| SCHEMBL28462259 | 0.88 | HTR1D (0.33) | KCNH2CACNA1CSCN5AIRAK4HTR1D | |
| SCHEMBL28462255 | 0.88 | HTR1D (0.33) | KCNH2CACNA1CSCN5AIRAK4HTR1D | |
| SCHEMBL8873531 | 0.85 | PLG (0.34) | KCNH2CACNA1CSCN5AIRAK4HTR1D | |
| SCHEMBL8873526 | 0.85 | PLG (0.34) | KCNH2CACNA1CSCN5AIRAK4HTR1D | |
| SCHEMBL2155119 | 0.81 | IRAK4 (0.32) | KCNH2CACNA1CSCN5AIRAK4HTR1D | |
| SCHEMBL5173514 | 0.81 | IRAK4 (0.32) | KCNH2CACNA1CSCN5AIRAK4HTR1D | |
| SCHEMBL24298899 | 0.81 | IRAK4 (0.32) | KCNH2CACNA1CSCN5AIRAK4HTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4504739-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2025-02-12 | — | — | EP | disclosed |
| WO-2023196429-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023196429-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-12 | — | — | WO | disclosed |
| EP-4225765-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| CN-116601158-A | Modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2023-08-15 | — | — | CN | disclosed |
| WO-2022076622-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022076622-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |